-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380

Benzinga·11/03/2026 15:48:38
Listen to the news
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.